Form 4: Lexicon Pharmaceuticals Director Judith L. Swain Reports Stock Transaction

Director Judith L. Swain reports a transaction involving Lexicon Pharmaceuticals common stock and restricted stock units on May 13, 2025.

Summary

• On May 13, 2025, Judith L. Swain, a director of Lexicon Pharmaceuticals, reported a transaction.
• The transaction involved the disposition of 36,810 shares of common stock and the acquisition of the same number of shares through the vesting of restricted stock units.
• Following the transaction, Swain directly owns 85,174 shares of Lexicon Pharmaceuticals common stock.
• The restricted stock units vest 100% on the first anniversary of the grant date and each unit represents one share of common stock.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing a stock transaction. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company insiders.

Stakeholder Impact

• The transaction may have a minor impact on shareholders due to the change in ownership, but it's unlikely to be significant given the size of the transaction relative to the company's overall market capitalization.

Key Dates

Keywords

Form 4, Beneficial Ownership, LXRX, Lexicon Pharmaceuticals, Judith L. Swain, Director, Stock Transaction, Restricted Stock Units, Common Stock